Loading...
•
Mar 31, 2021
Cytokinetics Q1 2021 Earnings Report
Reported financial results for the first quarter of 2021.
Key Takeaways
Cytokinetics reported a net loss of $47.1 million, or $0.66 per share, for the first quarter of 2021. Revenues increased to $6.5 million from $3.8 million for the first quarter of 2020. Cash, cash equivalents and investments totaled $460.2 million at March 31, 2021.
Net loss for the first quarter was $47.1 million, or $0.66 per share.
Revenues for the first quarter increased to $6.5 million from $3.8 million for the first quarter 2020.
Research and development expenses for the first quarter increased to $31.6 million from $21.7 million for the first quarter of 2020.
Cash, cash equivalents and investments totaled $460.2 million at March 31, 2021.
Forward Guidance
We expect to revise our financial guidance mid-year once we finalize strategies and potential commercial launch plans for omecamtiv mecarbil.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...